Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

An Erratum to this article was published on 11 September 2009

Abstract

Nowadays osteoporosis treatment is based primarily on therapy with antiresorptive agents, like the bisphosphonates. Parathyroid hormone (Preotact) and human recombinant parathyroid hormone peptide 1–34 (Teriparatide) are relatively new for the treatment of osteoporosis and belong to the group of anabolic agents. Both agents demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in postmenopausal women with osteoporosis when given for 18–24 months. Data on nonvertebral fractures are, however, not clear-cut, and so far only bisphosphonates and strontium ranelate have been demonstrated to reduce all types of fractures and therefore remain the front-line option for treatment of osteoporosis. As the safety, tolerability, and cost of the therapy also influence the choice of therapy, Preotact and Teriparatide might be useful additions to the armamentarium for (second-line) treatment of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ettinger MP (2003) Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 163:2237–2246

    Article  PubMed  Google Scholar 

  2. Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603

    Article  PubMed  CAS  Google Scholar 

  3. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP (1999) On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:1562–1566

    Article  PubMed  CAS  Google Scholar 

  4. Rubin MR, Bilezikian JP (2002) New anabolic therapies in osteoporosis. Curr Opin Rheumatol 14:433–440

    Article  PubMed  CAS  Google Scholar 

  5. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, Bilezikian JP, Klaushofer K (2007) New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res 22:717–723

    Article  PubMed  Google Scholar 

  6. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156

    Article  PubMed  CAS  Google Scholar 

  7. Roschger P, Paschalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42:456–466

    Article  PubMed  CAS  Google Scholar 

  8. Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1–34). Bone 28:237–250

    Article  PubMed  CAS  Google Scholar 

  9. Potts JT (2005) Parathyroid hormone: past and present. J Endocrinol 187:311–325

    Article  PubMed  CAS  Google Scholar 

  10. Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65:532–539

    Article  PubMed  CAS  Google Scholar 

  11. Whitfield JF, Morley P (1995) Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Trends Pharmacol Sci 16:382–386

    Article  PubMed  CAS  Google Scholar 

  12. Schwietert HR, Groen EW, Sollie FA, Jonkman JH (1997) Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 61:360–376

    Article  PubMed  CAS  Google Scholar 

  13. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F (1993) Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 77:1535–1539

    Article  PubMed  CAS  Google Scholar 

  14. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584

    Article  PubMed  CAS  Google Scholar 

  15. Ejersted C, Andreassen TT, Oxlund H, Jorgensen PH, Bak B, Haggblad J, Torring O, Nilsson MH (1993) Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 8:1097–1101

    Article  PubMed  CAS  Google Scholar 

  16. Samnegard E, Iwaniec UT, Cullen DM, Kimmel DB, Recker RR (2001) Maintenance of cortical bone in human parathyroid hormone(1–84)-treated ovariectomized rats. Bone 28:251–260

    Article  PubMed  CAS  Google Scholar 

  17. Dobnig H, Turner RT (1997) The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607–4612

    Article  PubMed  CAS  Google Scholar 

  18. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  PubMed  CAS  Google Scholar 

  19. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220

    Article  PubMed  CAS  Google Scholar 

  20. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339

    PubMed  Google Scholar 

  21. Moen MD, Scott LJ (2006) Recombinant full-length parathyroid hormone (1–84). Drugs 66:2371–2381

    Article  PubMed  CAS  Google Scholar 

  22. Greenspan SL, Hanley DA, Morris SA, Marriott TB (2006) Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1–84 (PTH). J Bone Miner Res 21:114

    Article  Google Scholar 

  23. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

  24. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565

    Article  PubMed  CAS  Google Scholar 

  25. Stroup JS, Rivers SM, Abu-Baker AM, Kane MP (2007) Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run Teriparatide clinic. Pharmacotherapy 27:779–788

    Article  PubMed  CAS  Google Scholar 

  26. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in bone mineral density correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180

    Article  PubMed  CAS  Google Scholar 

  27. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  28. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of Teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535

    Article  PubMed  CAS  Google Scholar 

  29. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555

    Article  PubMed  CAS  Google Scholar 

  30. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of Teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751

    Article  PubMed  CAS  Google Scholar 

  31. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of Teriparatide treatment in 30. postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860

    Article  PubMed  CAS  Google Scholar 

  32. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given Teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438

    Article  PubMed  CAS  Google Scholar 

  33. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of Teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  PubMed  CAS  Google Scholar 

  34. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516

    Article  PubMed  CAS  Google Scholar 

  35. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  PubMed  CAS  Google Scholar 

  36. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

    Article  PubMed  CAS  Google Scholar 

  37. Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R (2006) Initial experience with Teriparatide in the United States. Curr Med Res Opin 22:703–708

    Article  PubMed  CAS  Google Scholar 

  38. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443

    Article  PubMed  CAS  Google Scholar 

  39. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  40. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arth Rheum 58:1687–1695

    Article  CAS  Google Scholar 

  41. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 9:2816–2822

    Article  CAS  Google Scholar 

  42. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:95–96

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 4th Medicine Department, Hanusch Hospital, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, A-1140, Vienna, Austria

    Johannes Pleiner-Duxneuner, Elisabeth Zwettler, Eleftherios Paschalis, Paul Roschger, Valerie Nell-Duxneuner & Klaus Klaushofer

  2. Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

    Johannes Pleiner-Duxneuner

Authors
  1. Johannes Pleiner-Duxneuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth Zwettler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eleftherios Paschalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Roschger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valerie Nell-Duxneuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Klaus Klaushofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Pleiner-Duxneuner.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00223-009-9291-1

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pleiner-Duxneuner, J., Zwettler, E., Paschalis, E. et al. Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide. Calcif Tissue Int 84, 159–170 (2009). https://doi.org/10.1007/s00223-009-9218-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-009-9218-x

Keywords

Search

Navigation